Acolbifene/GnRH agonist/prasterone combination therapy - Endoceutics

Drug Profile

Acolbifene/GnRH agonist/prasterone combination therapy - Endoceutics

Alternative Names: Femitra; GnRH agonist/prasterone/acolbifene - Endoceutics

Latest Information Update: 23 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endoceutics
  • Class Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Dehydroepiandrosterone-replacements; Gonadotropin releasing hormone stimulants; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Endometriosis

Most Recent Events

  • 23 Jan 2018 NDR (Batch#13) - Added ADS because the product is listed on Endoceutics' pipeline
  • 23 Jan 2018 Phase-III development for Endometriosis is ongoing in Canada (PO, SC) (Endoceutics pipeline, January 2018)
  • 02 Dec 2015 Phase-III development for Endometriosis is ongoing in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top